Normalisation of angiogenic imbalance after intra-uterine transfusion for mirror syndrome caused by parvovirus B19

Fetal Diagnosis and Therapy

Volumn 34, Issue 3, 2013, Pages 176-179

  Goa, Satoko ^a   Mimura, Kazuya ^a   Kakigano, Aiko ^a   Tomimatsu, Takuji ^a   Kinugasa Taniguchi, Yukiko ^a   Endo, Masayuki ^a   Kanagawa, Takeshi ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Human chorionic gonadotropin; Mirror syndrome; Parvovirus B19; Placental growth factor; Soluble fms like tyrosine kinase 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHORIONIC GONADOTROPIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HEMOGLOBIN; HEMOGLOBIN F; IMMUNOGLOBULIN M; PROTEIN; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANTIBODY TITER; APGAR SCORE; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CARDIOMEGALY; CASE REPORT; DIURESIS; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE CONCENTRATE; FEMALE; FETUS ECHOGRAPHY; FETUS HYDROPS; GENERALIZED EDEMA; GESTATIONAL AGE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HIGH OUTPUT HEART FAILURE; HUMAN; HUMAN PARVOVIRUS B19; HYPERURICEMIA; INTRAUTERINE BLOOD TRANSFUSION; LEG EDEMA; MATERNAL SERUM; MIDDLE CEREBRAL ARTERY; MIRROR SYNDROME; NEWBORN; OLIGOHYDRAMNIOS; OLIGURIA; OXYGEN SATURATION; PARVOVIRUS INFECTION; PEAK SYSTOLIC VELOCITY; PLACENTA DISORDER; PLACENTOMEGALY; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; TRICUSPID VALVE REGURGITATION; URIC ACID BLOOD LEVEL; WEIGHT GAIN;

ADULT; BLOOD TRANSFUSION, INTRAUTERINE; CHORIONIC GONADOTROPIN; EDEMA; ERYTHEMA INFECTIOSUM; FEMALE; HUMANS; HYDROPS FETALIS; PREGNANCY; PREGNANCY PROTEINS; SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84887217727     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000348778     Document Type: Article

References (18)

1. Ohkuchi A, Hirashima C, Matsubara S, Takahashi K, Matsuda Y, Suzuki M: Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia. Hypertension 2011; 58: 859-866.
2. van Selm M, Kanhai HH, Gravenhorst JB: Maternal hydrops syndrome: a review. Obstet Gynecol Surv 1991; 46: 785-788.
3. Braun T, Brauer M, Fuchs I, Czernik C, Dudenhausen JW, Henrich W, Sarioglu N: Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagn Ther 2010; 27: 191-203.
4. Espinoza J, Romero R, Nien JK, Kusanovic JP, Richani K, Gomez R, Kim CJ, Mittal P, Gotsh F, Erez O, Chaiworapongsa T, Hassan S: A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). J Matern Fetal Neonatal Med 2006; 19: 607-613.
5. Vidaeff AC, Pschirrer ER, Mastrobattista JM, Gilstrap LC III, Ramin SM: Mirror syndrome. A case report. J Reprod Med 2002; 47: 770-774.
6. Carbillon L, Oury JF, Guerin JM, Azancot A, Blot P: Clinical biologic features of Ballantyne syndrome and the role of placental hydrops. Obstet Gynecol Surv 1997; 52: 310-314.
7. Dekker GA, Sibai BM: Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179: 1359-1375.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
9. Stepan H, Faber R: Elevated sFlt1 level and preeclampsiawith parvovirus-induced hydrops. N Engl J Med 2006; 354: 1857-1858.
10. Llurba E, Marsal G, Sanchez O, Dominguez C, Alijotas-Reig J, Carreras E, Cabero L: Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. Ultrasound Obstet Gynecol 2012; 40: 367-369.
11. Carraca T, Matias A, Brandão O, Montenegro N: Early signs of cardiac failure: a clue for parvovirus infection screening in the first trimester? Fetal Diagn Ther 2011; 30: 150-152.
12. Gherman RB, Incerpi MH, Wing DA, Goodwin TM: Ballantyne syndrome: is placental ischemia the etiology? J Matern-Fetal Med 1998; 7: 227-229.
13. Gurbuz A, Karateke A, Mengulluoglu M, Gedikbasi A, Ozturkmen M, Kabaca C, Sahinoglu Z: Can serum HCG values be used in the differential diagnosis of pregnancy complicated by hypertension? Hypertens Pregnancy 2004; 23: 1-12.
14. Brouillet S, Hoffmann P, Chauvet S, Salomon A, Chamboredon S, Sergent F, Benharouga M, Feige JJ, Alfaidy N: Revisiting the role of hCG: new regulation of the angiogenic factor EG-VEGF and its receptors. Cell Mol Life Sci 2012; 69: 1537-1550.
15. Heyborne KD, Chism DM: Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med 2000; 45: 360-362.
16. Duthie SJ, Walkinshaw SA: Parvovirus associated fetal hydrops: reversal of pregnancy induced proteinuric hypertension by in utero fetal transfusion. Br J Obstet Gynaecol 1995; 102: 1011-1013.
17. Dembinski J, Haverkamp F, Maara H, Hansmann M, Eis-Hubinger AM, Bartmann P: Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. Br J Obstet Gynecol 2002; 109: 1232-1234.
18. Chauvet A, Dewilde A, Thomas D, Joriot S, Vaast P, Houfflin-Debarge V, Subtil D: Ultrasound diagnosis, management and prognosis in a consecutive series of 27 cases of fetal hydrops following maternal parvovirus B19 infection. Fetal Diagn Ther 2011; 30: 41-47.